Teleflex第三季度营收5.68亿美元：调整后每股收益增至2.63美元，上调全年指引
总部位于宾夕法尼亚州特拉华县 Wayne 的医疗技术公司 Teleflex Incorporated（纽交所：TFX）11月5日公布截至9月30日的2026年第三季度业绩：持续经营营收5.678亿美元，同比增长0.2%，按备考调整后固定汇率口径增长3.0%。
当季持续经营 GAAP 摊薄每股收益为1.30美元，上年同期为每股亏损1.32美元；调整后摊薄每股收益为2.63美元，上年同期为1.89美元。分部营收方面，血管业务2.435亿美元，增长4.7%；介入业务2.103亿美元；外科业务1.140亿美元，增长4.2%。当季持续经营确认了2,530万美元的关税退款收益，公司第三季度收到的 IEEPA 关税退款总额为3,920万美元。
资本配置方面，公司自第三季度开始至本稿发布已回购约3.5亿美元普通股，其中包括完成2.5亿美元加速回购计划及另行1亿美元公开市场回购；截至11月5日，现行回购授权下尚余4亿美元可用。公司8月已完成 OEM 业务以15亿美元现金出售，急性护理与介入泌尿业务向 Intersurgical Ltd. 的出售仍在推进，目标2026年底前完成交割。
公司上调全年持续经营调整后摊薄每股收益指引至7.50至7.75美元，GAAP 每股收益指引上调至2.84至3.09美元；GAAP 营收增速指引因汇率变化下调至13.2%至14.2%，备考调整后固定汇率增速指引维持3.5%至4.5%。
总裁兼首席执行官 Jason Weidman 表示：「我们对第三季度的表现感到满意，包括利润率扩张和每股收益的强劲增长——即使剔除 IEEPA 关税退款也是如此。」（来源：Teleflex）
Teleflex Q3 Revenue Reaches $567.8 Million: Adjusted EPS Rises to $2.63 as Full-Year Guidance Is Raised
Teleflex Incorporated (NYSE: TFX), a medical technology company based in Wayne, Delaware County, Pennsylvania, reported results on November 5 for the third quarter ended September 30, 2026: revenue from continuing operations was $567.8 million, up 0.2% year over year and up 3.0% on a pro forma adjusted constant-currency basis.
GAAP diluted EPS from continuing operations was $1.30, compared with a loss of $1.32 a year earlier; adjusted diluted EPS was $2.63, compared with $1.89. By segment, Vascular revenue was $243.5 million, up 4.7%; Interventional was $210.3 million; and Surgical was $114.0 million, up 4.2%. Continuing operations recognized a $25.3 million benefit from tariff refunds in the quarter, within total IEEPA tariff refunds of $39.2 million received in the quarter.
On capital allocation, the company repurchased about $350 million of common stock from the start of the third quarter through the release, completing a $250 million accelerated share repurchase plus $100 million of open-market purchases; $400 million remained under the current authorization as of November 5. The $1.5 billion cash sale of the OEM business closed in August, and the sale of the Acute Care and Interventional Urology businesses to Intersurgical Ltd. continues to advance toward a targeted close by year-end 2026.
Teleflex raised its full-year adjusted diluted EPS guidance from continuing operations to $7.50 to $7.75 and its GAAP EPS guidance to $2.84 to $3.09; GAAP revenue growth guidance was reduced to 13.2% to 14.2% on foreign-exchange changes, while pro forma adjusted constant-currency growth guidance was maintained at 3.5% to 4.5%.
"We are pleased with our third quarter performance, which included margin expansion and robust earnings per share growth, even when excluding IEEPA tariff refunds," said Jason Weidman, Teleflex's President and Chief Executive Officer. (Source: Teleflex)
来源：Teleflex
发布：GSM·美国（发布链接）
图片来源：图：宾夕法尼亚州 Philadelphia 天际线，Teleflex 总部 Wayne 位于其都会区。Bmoredlj 摄，公共领域，经 Wikimedia Commons。 / Photo: The Philadelphia skyline in Pennsylvania; Teleflex's headquarters in Wayne is in its metropolitan area. By Bmoredlj, public domain, via Wikimedia Commons.
GSM Global · 本篇英文版 English edition of this story
